308 related articles for article (PubMed ID: 22362605)
1. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis.
Beuck S; Schänzer W; Thevis M
Drug Test Anal; 2012 Nov; 4(11):830-45. PubMed ID: 22362605
[TBL] [Abstract][Full Text] [Related]
2. Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research.
Beuck S; Bornatsch W; Lagojda A; Schänzer W; Thevis M
Drug Test Anal; 2011; 3(11-12):756-70. PubMed ID: 22213684
[TBL] [Abstract][Full Text] [Related]
3. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.
Buisson C; Marchand A; Bailloux I; Lahaussois A; Martin L; Molina A
J Pharm Biomed Anal; 2016 Mar; 121():181-187. PubMed ID: 26808067
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
5. Cobalt chloride administration in athletes: a new perspective in blood doping?
Lippi G; Franchini M; Guidi GC
Br J Sports Med; 2005 Nov; 39(11):872-3. PubMed ID: 16244201
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
Dib J; Mongongu C; Buisson C; Molina A; Schänzer W; Thuss U; Thevis M
Drug Test Anal; 2017 Jan; 9(1):61-67. PubMed ID: 27346747
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-stimulating agents: development, detection and dangers.
Franz SE
Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
[TBL] [Abstract][Full Text] [Related]
8. Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine.
De Wilde L; Roels K; Deventer K; Van Eenoo P
Biomed Chromatogr; 2021 Feb; 35(2):e4970. PubMed ID: 32840903
[TBL] [Abstract][Full Text] [Related]
9. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
10. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
[TBL] [Abstract][Full Text] [Related]
11. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
Gosetti F; Mazzucco E; Gennaro MC; Marengo E
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
[TBL] [Abstract][Full Text] [Related]
12. Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry?
Elliott S; Leishman B
Bioanalysis; 2012 Jul; 4(13):1681-90. PubMed ID: 22831483
[TBL] [Abstract][Full Text] [Related]
13. Intolerability of cobalt salt as erythropoietic agent.
Ebert B; Jelkmann W
Drug Test Anal; 2014 Mar; 6(3):185-9. PubMed ID: 24039233
[TBL] [Abstract][Full Text] [Related]
14. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
[TBL] [Abstract][Full Text] [Related]
15. Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.
Leuenberger N; Reichel C; Lasne F
Bioanalysis; 2012 Jul; 4(13):1565-75. PubMed ID: 22831473
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin and erythropoiesis stimulating agents.
Debeljak N; Sytkowski AJ
Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
[TBL] [Abstract][Full Text] [Related]
17. Blood doping: risks to athletes' health and strategies for detection.
Oliveira CD; Bairros AV; Yonamine M
Subst Use Misuse; 2014 Jul; 49(9):1168-81. PubMed ID: 24766400
[TBL] [Abstract][Full Text] [Related]
18. Detection of peptidic erythropoiesis-stimulating agents in sport.
Reichel C
Br J Sports Med; 2014 May; 48(10):842-7. PubMed ID: 24677025
[TBL] [Abstract][Full Text] [Related]
19. Metabolic studies of hypoxia-inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control.
Philip M; Mathew B; Karatt TK; Perwad Z; Subhahar MB; Karakka Kal AK
Drug Test Anal; 2021 Apr; 13(4):794-816. PubMed ID: 33458935
[TBL] [Abstract][Full Text] [Related]
20. Multiplexed detection of agents affecting erythropoiesis (AAEs) and overall strategy for optimizing initial testing procedure.
Martin L; Ericsson M; Marchand A
Drug Test Anal; 2021 Oct; 13(10):1791-1796. PubMed ID: 34342157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
